No Data
No Data
BofA Securities Maintains Werewolf Therapeutics(HOWL.US) With Buy Rating, Maintains Target Price $10
Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference
Werewolf Therapeutics Analyst Ratings
Werewolf Therapeutics Advances Innovative Cytokine Therapies
Leerink Partners Maintains Werewolf Therapeutics(HOWL.US) With Buy Rating, Maintains Target Price $13
Promising Potential of Werewolf Therapeutics' INDUKINE Platform Despite Challenges